Seroprevalence of anti-SARS-CoV-2 IgG at the epidemic peak in French Guiana. Preprint
General Info
Coverage type
Country
Time period covered
July, 2020 - July, 2020
Data type
Scientific literature
Summary
"The overall seroprevalence was 15.4% [9.3%-24.4%] among 480 participants, ranging from 4.0% to 25.5% across the different municipalities. The seroprevalence did not differ according to gender (p=0.19) or age (p=0.51). Among SARS-CoV-2 positive individuals, we found that 24.6% [11.5%-45.2%] reported symptoms consistent with COVID-19."
Keywords
Citation
Journal
medRxiv
Suggested citation
Flamand C, Enfissi A, Bailly S, Sarmento CA, Beillard E, Gaillet M, Michaud C, Servas V, Clement N, Perilhou A, Carage T, Musso D, Carod J-F, Eustache S, Tourbillon C, Boizon E, James S, Djossou F, Salje H, Cauchemez S, Rousset D.
Seroprevalence of anti-SARS-CoV-2 IgG at the epidemic peak in French Guiana. Preprint. medRxiv. 2020.